secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERUS CORP (CERS)
CIK:        0001020214
Form:       8-K
Filed at:   2022-07-05T23:59:59+00:00
Accession:  0001193125-22-187995
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cerus appoints Dr. Hua Shan to Board of Directors effective July 1, 2022
------------------------------------------------------------------------

- Dr. Hua Shan, Medical Director of Transfusion Medicine at Stanford, joins Cerus Board effective July 1, 2022.
- She brings over 25 years of transfusion medicine experience, including expertise in Chinese blood bank practices.
- Receives $45k annual cash retainer and initial equity grants valued at $150k in options and $150k in RSUs, vesting over 3 years.
- Appointment supports Cerus's JV to bring INTERCEPT Blood System to China and global expansion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1020214/000119312522187995/0001193125-22-187995-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1020214/000119312522187995/d357061d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-187995

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer